title: Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type.
abstract: BACKGROUND
  The evaluation of first-line intensive combination therapy in small cell carcinoma of the ovary (SCCO).
  
  
  METHODS
  Debulking surgery; four to six cycles of chemotherapy with cisplatin (P) 80 mg/m(2) day 1, adriamycin (A) 40 mg/m(2) day 1, vepeside (V) 75 mg/m(2)/day days 1-3, cyclophosphamide (EP) 300 mg/m(2)/day days 1-3, every 3 weeks and granulocyte colony-stimulating factor with, in case of a complete remission, high-dose chemotherapy with carboplatin, vepeside, cyclophosphamide and stem-cell support.
  
  
  RESULTS
  Twenty-seven patients (median age 25 years); International Federation of Gynecology and Obstetrics stage: five I, four IIC, 17 IIIC-IV and one unknown. Twenty patients underwent complete surgery. Eight patients progressed under chemotherapy. Among 18 patients in complete response (CR), 10 received high-dose chemotherapy (CT) (three stem-cell collection failures, two protocol violations, two disease progression and one refusal). The main grade 3-4 toxic effects were hematologic. There were eight relapses among the 18 CR, four of which were pelvic alone. Among the 27 patients, 13 died and 10 patients are in CR1, three in CR2. The median follow-up is 37 months (8-166) and the median duration of the 18 CR is 30 months (5-111). Overall survival at 1 and 3 years is 58% [confidence interval (CI) 40% to 75%] and 49% (CI 30% to 67%).
  
  
  CONCLUSIONS
  Initial dose-intensive therapy achieves interesting overall survival in SCCO.
authors.affiliation: Department of Medical Oncology, Institut Gustave-Roussy, Villejuif, France. pautier@igr.fr
authors.forename: P
authors.initials: P
authors.lastname: Pautier
authors.forename: V
authors.initials: V
authors.lastname: Ribrag
authors.forename: P
authors.initials: P
authors.lastname: Duvillard
authors.forename: A
authors.initials: A
authors.lastname: Rey
authors.forename: I
authors.initials: I
authors.lastname: Elghissassi
authors.forename: I
authors.initials: I
authors.lastname: Sillet-Bach
authors.forename: P
authors.initials: P
authors.lastname: Kerbrat
authors.forename: F
authors.initials: F
authors.lastname: Mayer
authors.forename: A
authors.initials: A
authors.lastname: Lesoin
authors.forename: B
authors.initials: B
authors.lastname: Brun
authors.forename: H
authors.initials: H
authors.lastname: Crouet
authors.forename: J C
authors.initials: JC
authors.lastname: Barats
authors.forename: P
authors.initials: P
authors.lastname: Morice
authors.forename: C
authors.initials: C
authors.lastname: Lhommé
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000150:complications / Q000188:drug therapy*; D002648:Child; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000150:complications*; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D016896:Treatment Outcome